Report for: Rituximab in severe skin diseases: target, disease, and dose

Title	Rituximab in severe skin diseases: target, disease, and dose
Published in	Clinical Pharmacology : Advances and Applications, July 2014
DOI	10.2147/cpaa.s10929
Pubmed ID	22291497
Authors	Daniel D Bennett, Maro Ohanian, Christian T Cable
Abstract	New clinical indications for rituximab seem to appear every day. This review will trace the use of this monoclonal antibody from lymphoid malignancy, to classic autoimmune disease, and specifically severe autoimmune skin diseases. The history leading to different dosing schema with associated pharmacokinetic data will be discussed. A case of livedoid vasculopathy (atrophie blanche) responding to rituximab will illustrate how the response to therapy can help to elucidate previously obscure pathophysiology.

View on publisher site Alert me about new mentions

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country	Count	As %
Unknown	14	100%

Demographic breakdown

Readers by professional status	Count	As %
Student > Master	2	14%
Researcher	2	14%
Student > Bachelor	2	14%
Unspecified	1	7%
Lecturer > Senior Lecturer	1	7%
Other	2	14%
Unknown	4	29%

Readers by discipline	Count	As %
Medicine and Dentistry	6	43%
Biochemistry, Genetics and Molecular Biology	1	7%
Unspecified	1	7%
Chemistry	1	7%
Agricultural and Biological Sciences	1	7%
Other	0	0%
Unknown	4	29%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 July 2014.

All research outputs

#3,777,193

of 22,758,248 outputs

Outputs from Clinical Pharmacology : Advances and Applications

#29

of 170 outputs

Outputs of similar age

#37,331

of 225,737 outputs

Outputs of similar age from Clinical Pharmacology : Advances and Applications

of 4 outputs

Altmetric has tracked 22,758,248 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.

So far Altmetric has tracked 170 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done well, scoring higher than 81% of its peers.

Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 225,737 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.

We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them

Dove Medical Press

Article Metrics

Rituximab in severe skin diseases: target, disease, and dose

About this Attention Score

Mentioned by

Citations

Readers on

Mendeley readers

Geographical breakdown

Demographic breakdown

Attention Score in Context